Gilead Sciences [GILD] vs Eli Lilly and [LLY] Detailed Stock Comparison
Gilead Sciences
NASDAQ
Loading...
Eli Lilly and
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Gilead Sciences wins in 10 metrics, Eli Lilly and wins in 10 metrics, with 0 ties. Both stocks appear equally matched on key metrics.
View Metrics Details
Vital Metrics Comparison
| Metric | Gilead Sciences | Eli Lilly and | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 22.21 | 47.62 | Gilead Sciences |
| Price-to-Book Ratio | 7.11 | 35.83 | Gilead Sciences |
| Debt-to-Equity Ratio | 127.34 | 217.89 | Gilead Sciences |
| PEG Ratio | 1.02 | 0.52 | Eli Lilly and |
| EV/EBITDA | 11.49 | 27.80 | Gilead Sciences |
| Profit Margin (TTM) | 21.87% | 25.91% | Eli Lilly and |
| Operating Margin (TTM) | 39.16% | 45.81% | Eli Lilly and |
| EBITDA Margin (TTM) | 39.16% | 45.81% | Eli Lilly and |
| Return on Equity | 33.40% | 86.29% | Eli Lilly and |
| Return on Assets (TTM) | 12.62% | 16.55% | Eli Lilly and |
| Free Cash Flow (TTM) | $10.31B | $414.30M | Gilead Sciences |
| Dividend Yield | 3.25% | 0.52% | Gilead Sciences |
| 1-Year Return | 30.70% | -7.59% | Gilead Sciences |
| Price-to-Sales Ratio (TTM) | 4.84 | 12.29 | Gilead Sciences |
| Enterprise Value | $158.54B | $688.73B | Eli Lilly and |
| EV/Revenue Ratio | 5.49 | 12.93 | Gilead Sciences |
| Gross Profit Margin (TTM) | 78.80% | 84.27% | Eli Lilly and |
| Revenue per Share (TTM) | $23 | $59 | Eli Lilly and |
| Earnings per Share (Diluted) | $5.07 | $15.33 | Eli Lilly and |
| Beta (Stock Volatility) | 0.38 | 0.47 | Gilead Sciences |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Gilead Sciences vs Eli Lilly and Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Gilead Sciences | 1.94% | -0.39% | -1.91% | -0.85% | -1.19% | 20.33% |
| Eli Lilly and | 2.46% | 14.73% | 11.52% | 5.21% | 0.20% | 5.37% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Gilead Sciences | 30.70% | 71.97% | 73.18% | 9.85% | 508.48% | 830.64% |
| Eli Lilly and | -7.59% | 150.98% | 422.60% | 851.76% | 2,111.63% | 1,435.01% |
News Based Sentiment: Gilead Sciences vs Eli Lilly and
Gilead Sciences
News based Sentiment: MIXED
October was a largely positive month for Gilead, with strong earnings and analyst upgrades offset by potential drug pricing pressures. The company's significant investments in R&D and manufacturing signal a commitment to long-term growth, but the Biktarvy pricing issue introduces a notable risk factor, creating a mixed overall investment narrative.
Eli Lilly and
News based Sentiment: POSITIVE
September was a highly significant month for Eli Lilly, characterized by substantial investments in manufacturing capacity ($11.5 billion total), key regulatory approvals for Inluriyo and Kisunla, and strong Q2 financial performance with raised guidance. These developments collectively reinforce the company's growth trajectory and strengthen its position in key therapeutic areas.
Performance & Financial Health Analysis: Gilead Sciences vs Eli Lilly and
| Metric | GILD | LLY |
|---|---|---|
| Market Information | ||
| Market Cap | $139.74B | $658.23B |
| Market Cap Category | Large cap | Mega cap |
| 10 Day Avg. Volume | 7,201,150 | 3,403,336 |
| 90 Day Avg. Volume | 6,413,223 | 3,481,179 |
| Last Close | $112.71 | $840.02 |
| 52 Week Range | $83.98 - $121.83 | $623.78 - $937.00 |
| % from 52W High | -7.49% | -10.35% |
| All-Time High | $123.37 (Jun 22, 2015) | $972.53 (Aug 19, 2024) |
| % from All-Time High | -8.64% | -13.63% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.02% | 0.38% |
| Quarterly Earnings Growth | 0.21% | 0.91% |
| Financial Health | ||
| Profit Margin (TTM) | 0.22% | 0.26% |
| Operating Margin (TTM) | 0.39% | 0.46% |
| Return on Equity (TTM) | 0.33% | 0.86% |
| Debt to Equity (MRQ) | 127.34 | 217.89 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $15.84 | $20.38 |
| Cash per Share (MRQ) | $4.88 | $3.95 |
| Operating Cash Flow (TTM) | $9.87B | $10.94B |
| Levered Free Cash Flow (TTM) | $8.84B | $-2,265,437,440 |
| Dividends | ||
| Last 12-Month Dividend Yield | 3.25% | 0.52% |
| Last 12-Month Dividend | $3.91 | $4.10 |
Valuation & Enterprise Metrics Analysis: Gilead Sciences vs Eli Lilly and
| Metric | GILD | LLY |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 22.21 | 47.62 |
| Forward P/E | 15.16 | 32.21 |
| PEG Ratio | 1.02 | 0.52 |
| Price to Sales (TTM) | 4.84 | 12.29 |
| Price to Book (MRQ) | 7.11 | 35.83 |
| Market Capitalization | ||
| Market Capitalization | $139.74B | $658.23B |
| Enterprise Value | $158.54B | $688.73B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 5.49 | 12.93 |
| Enterprise to EBITDA | 11.49 | 27.80 |
| Risk & Other Metrics | ||
| Beta | 0.38 | 0.47 |
| Book Value per Share (MRQ) | $15.84 | $20.38 |
Financial Statements Comparison: Gilead Sciences vs Eli Lilly and
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | GILD | LLY |
|---|---|---|
| Revenue/Sales | $6.67B | $15.56B |
| Cost of Goods Sold | $1.54B | $2.45B |
| Gross Profit | $5.13B | $13.11B |
| Research & Development | $1.38B | $3.34B |
| Operating Income (EBIT) | $2.49B | $7.13B |
| EBITDA | $3.28B | $7.54B |
| Pre-Tax Income | $1.65B | $6.78B |
| Income Tax | $334.00M | $1.12B |
| Net Income (Profit) | $1.32B | $5.66B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | GILD | LLY |
|---|---|---|
| Cash & Equivalents | $7.93B | $3.09B |
| Total Current Assets | $16.90B | $41.26B |
| Total Current Liabilities | $12.34B | $30.07B |
| Long-Term Debt | $22.15B | $34.50B |
| Total Shareholders Equity | $19.08B | $15.85B |
| Retained Earnings | $10.93B | $15.10B |
| Property, Plant & Equipment | $7.96B | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | GILD | LLY |
|---|---|---|
| Operating Cash Flow | $1.56B | $4.88B |
| Capital Expenditures | $-104.00M | $-1.51B |
| Free Cash Flow | $1.65B | $-1.60B |
| Debt Repayment | $-1.76B | N/A |
| Common Stock Repurchase | $-730.00M | $-1.20B |
Short Interest & Institutional Ownership Analysis
| Metric | GILD | LLY |
|---|---|---|
| Shares Short | 18.25M | 7.32M |
| Short Ratio | 2.97 | 1.93 |
| Short % of Float | 0.01% | 0.01% |
| Average Daily Volume (10 Day) | 7,201,150 | 3,403,336 |
| Average Daily Volume (90 Day) | 6,413,223 | 3,481,179 |
| Shares Outstanding | 1.25B | 897.54M |
| Float Shares | 1.24B | 895.44M |
| % Held by Insiders | 0.00% | 0.00% |
| % Held by Institutions | 0.91% | 0.84% |
Dividend Analysis & Yield Comparison: Gilead Sciences vs Eli Lilly and
| Metric | GILD | LLY |
|---|---|---|
| Last 12-Month Dividend | $3.91 | $4.10 |
| Last 12-Month Dividend Yield | 3.25% | 0.52% |
| 3-Year Avg Annual Dividend | $3.30 | $4.02 |
| 3-Year Avg Dividend Yield | 0.91% | 0.22% |
| 3-Year Total Dividends | $9.91 | $12.05 |
| Ex-Dividend Date | Sep 15, 2025 | Feb 14, 2025 |